This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): FORMA/BI Program
Description: FORMA and Boehringer Ingelheim's novel collaboration program will develop small molecule drugs against oncology-relevant protein-protein interaction (PPI) targets.
FORMA and Boehringer Ingelheim
In January 2012, FORMA and Boehringer Ingelheim signed a research and development collaboration deal to discover small molecule drugs against oncology-relevant protein-protein interaction (PPI) targets.
Partners: Boehringer Ingelheim GmbH
FORMA/BI Program News
Additional information available to subscribers only: